Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that the
United Kingdom High Court of Justice issued a decision in favor of Teva
in a patent litigation proceeding against Generics (UK) Limited, a
subsidiary of Mylan Laboratories Inc., on July 11, 2012. Generics (UK)
Limited commenced the proceeding in the UK to seek the revocation of
European Patent (UK) 762,888, a patent for COPAXONE® (glatiramer acetate
injection) expiring May 23, 2015, and to obtain a declaration that its
proposed generic version of COPAXONE® would not infringe the '888
patent. The High Court specifically determined that the asserted claims
of the '888 patent were valid, and also declined to issue a declaration
that Generics UK's proposed generic version of COPAXONE® would not
infringe the '888 patent.
Any potential generic version of COPAXONE® would require a marketing
authorization from the Medicines and Healthcare products Regulatory
Agency (MHRA) before it could be commercialized.